Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02587962 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
A Phase 1 study, sponsored by Medivir.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02587962 is a Phase 1 study that was terminated before completion, run by Medivir. The registered enrollment target is 34 participants.
The verdict
NCT02587962, a Phase 1 study, was terminated before completion, sponsored by Medivir.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of birinapant when given in combination with pembrolizumab. A dose expansion phase of 4 cohorts will also be included.
Interventions
- DRUG Pembrolizumab
- DRUG Birinapant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-08-04 |
| Est. Completion | 2020-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02587962
The ClinicalTrials.gov registry entry for NCT02587962 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medivir, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02587962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02587962 about?
NCT02587962 is a clinical study titled "Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors". An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of birinapant when given in combination with pembrolizumab. A dose expansion phase of 4 cohorts will also be included.
What is the current status of trial NCT02587962?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-08-04. Estimated completion is 2020-02-17.
What interventions are being tested in trial NCT02587962?
The interventions under investigation include: Pembrolizumab (DRUG), Birinapant (DRUG).
Who is sponsoring clinical trial NCT02587962?
This trial is sponsored by Medivir, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.